SOLICITATION NOTICE
A -- Development of Improved DTPA for Radionuclide Chelation
- Notice Date
- 7/16/2008
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- HHSN266200500047P
- Point of Contact
- Donald E Collie,, Phone: 301-496-0992
- E-Mail Address
-
dcollie@niaid.nih.gov
- Small Business Set-Aside
- N/A
- Description
- Introduction: The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology, and Transplantation (NIAID/DAIT) has a requirement to identify, characterize, and develop new medical countermeasures against radiological or nuclear attacks. Description: NIAID/DAIT plans to issue a Request for Proposal (RFP) to SRI International. An Offeror would conduct research and development on a DTPA formulation using absorption enhancers with improved oral bioavailability over the licensed DTPA products and which demonstrates decorporation of radionculdies. The Offeror, if awarded, would be required to prepare DTPA formulations using absorption enhancers and evaluate DTPA bioavailability, radionuclide decorporating efficacy, and toxicity of these formulations. Offeror would be required, for example, to demonstrate and document the following: 1) A lead DTPA formulation using absorption enhancers that has shown improved oral bioavailability over the licensed Ca- or Zn-DTPA product administered orally. 2) Assays in place for detecting DTPA in biological fluids. 3) Decorporation data using a candidate formulation. It is anticipated that a fixed price contract shall be awarded to a single contractor for a 1-year period of performance beginning on or about September 30, 2008, pending the availability of funds and receipt of technically acceptable proposals from the contractor. The estimated FTEs would be approximately 3.15, inclusive of work subcontracted to institutions within the United States. In addition, the Offeror will provide a proposal to accomplish the above requirements for the 1 year period of planned funding. The anticipated release date of the RFP is on or about September 1, 2008, with an anticipated offer due date on or about September 16, 2008. The firm date of receipt of offers will be stated in the RFP. This notice does not commit the Government to award the contract. No collect calls or facsimile transmissions will be accepted.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=26b9db44c3311e66c267341744d0f253&tab=core&_cview=1)
- Record
- SN01615405-W 20080718/080716221043-26b9db44c3311e66c267341744d0f253 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |